Insider Selling: Denali Therapeutics (NASDAQ:DNLI) Insider Sells 2,937 Shares of Stock

Key Points

• Denali Therapeutics insider Alexander O. Schuth sold 2,937 shares at an average price of $13.58, resulting in a total transaction value of $39,884.46, reducing their ownership by 1.20%.
• Denali Therapeutics stock experienced a decline of 2.4%, closing at $14.46, with analysts forecasting a -2.71 EPS for the current fiscal year.
• Research analysts have mixed ratings on Denali Therapeutics, with a consensus target price averaging $33.85, highlighting a strong buy sentiment among multiple analysts.

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) insider Alexander O. Schuth sold 2,937 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total transaction of $39,884.46. Following the transaction, the insider directly owned 242,346 shares of the company's stock, valued at approximately $3,291,058.68. This represents a 1.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Denali Therapeutics Trading Down 0.9%

DNLI traded down $0.1350 on Tuesday, reaching $14.6850. 191,318 shares of the company's stock were exchanged, compared to its average volume of 1,404,887. The company's 50 day moving average is $14.30 and its 200-day moving average is $15.19. The company has a market cap of $2.15 billion, a price-to-earnings ratio of -5.24 and a beta of 1.36. Denali Therapeutics Inc. has a twelve month low of $10.57 and a twelve month high of $33.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.27 and a current ratio of 10.27.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.72) earnings per share for the quarter, topping analysts' consensus estimates of ($0.74) by $0.02. During the same period in the previous year, the firm posted ($0.59) earnings per share. Equities analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Wall Street Analyst Weigh In

DNLI has been the subject of a number of analyst reports. TD Cowen upgraded Denali Therapeutics to a "strong-buy" rating in a report on Monday, July 28th. HC Wainwright lowered their price target on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Bank of America lowered their target price on Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a report on Monday, May 19th. William Blair raised Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Wedbush dropped their price target on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $33.62.

Institutional Trading of Denali Therapeutics

Institutional investors have recently made changes to their positions in the business. Headlands Technologies LLC acquired a new stake in shares of Denali Therapeutics during the 2nd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd raised its stake in Denali Therapeutics by 277.0% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock worth $29,000 after acquiring an additional 1,551 shares in the last quarter. Sterling Capital Management LLC grew its holdings in shares of Denali Therapeutics by 589.9% during the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after purchasing an additional 1,516 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Denali Therapeutics during the first quarter worth $41,000. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Denali Therapeutics during the fourth quarter worth $62,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.